Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 380 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vascular Inflammation Clear all
Completed No phase listed Observational Accepts healthy volunteers Results available

Risk Factors, Costs, and Impacts of ED Boarding

NCT07532564
View directory record Official record
Conditions
Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease), Sepsis, Hypertension, Heart Failure, Pneumonia, Urinary Tract Infection (Diagnosis), Chest Pain, Psychiatric Disorder, Sickle Cell Disease (SCD)
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
30,486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 23, 2026, 12:12 PM EDT
Completed No phase listed Observational

Coagulation Changes Associated With COVID-19 Infection

NCT04460664
View directory record Official record
Conditions
COVID, Disseminated Intravascular Coagulation, Coagulation Disorder
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 23, 2026, 12:12 PM EDT
Withdrawn Not applicable Interventional

Brachial Artery t-PA Release in Heart Transplant Recipients

NCT00780637
View directory record Official record
Conditions
Heart Transplantation
Interventions
Bradykinin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 23, 2026, 12:12 PM EDT
Not listed Phase 4 Interventional

Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy

NCT04059679
View directory record Official record
Conditions
Coronary Artery Disease, Peripheral Artery Disease
Interventions
Rivaroxaban 2.5 Mg Oral Tablet, Aspirin 81 mg
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 23, 2026, 12:12 PM EDT
Terminated Phase 2 Interventional

Single Dose Enteral Tranexamic Acid in Critically Ill Patients

NCT01683747
View directory record Official record
Conditions
Shock, Sepsis, Hypotension, Critical Illness
Interventions
Tranexamic Acid, Control Intervention (Carrier fluid only)
Drug
Lead sponsor
San Diego Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 23, 2026, 12:12 PM EDT
Not yet recruiting Phase 2 Interventional

Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans

NCT07602166
View directory record Official record
Conditions
Salt Sensitivity of Blood Pressure, High Blood Pressure, Inflammation, Renin-Angiotensin-Aldosterone System
Interventions
2-hydroxybenzylamine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 23, 2026, 12:12 PM EDT
Terminated No phase listed Observational

Understanding Coagulation and Inflammation in Burns

NCT03077269
View directory record Official record
Conditions
Burns
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 110 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 12:12 PM EDT
Completed Not applicable Interventional

Trial of Aerobic Exercise Training in Stroke Survivors

NCT00891514
View directory record Official record
Conditions
Stroke, Insulin Resistance, Sedentary Lifestyle
Interventions
Aerobic Exercise, Stretching
Behavioral
Lead sponsor
Baltimore VA Medical Center
Federal
Eligibility
40 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 23, 2026, 12:12 PM EDT
Completed No phase listed Observational Results available

Vascular Risk After Kidney Transplantation

NCT00374595
View directory record Official record
Conditions
Cardiovascular Disease, Chronic Kidney Disease, Diabetes, Vitamin D Deficiency, Hyperparathyroidism
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 23, 2026, 12:12 PM EDT
Recruiting Phase 2 Interventional

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

NCT06927739
View directory record Official record
Conditions
Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease, Myocardial Infarct, Atherosclerotic Coronary Vascular Disease
Interventions
Orticumab, Placebo
Drug
Lead sponsor
Abcentra
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Torrance, California • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 23, 2026, 12:12 PM EDT
Completed Phase 2 Interventional Results available

Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications

NCT00796822
View directory record Official record
Conditions
HIV, Cardiovascular Diseases, Atherosclerosis
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 23, 2026, 12:12 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Whey Protein Effects on Gycemic Control and Vascular Function

NCT01814358
View directory record Official record
Conditions
Blood Sugar (Glucose) Control, Blood Vessel (Vascular) Dysfunction
Interventions
Whey protein powder, Control protein
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 23, 2026, 12:12 PM EDT
Not listed Phase 3 Interventional

ARISE - Aggressive Reduction of Inflammation Stops Events

NCT00066898
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease, Myocardial Infarction, Unstable Angina
Interventions
AGI-1067
Drug
Lead sponsor
AtheroGenics
Industry
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
128
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 108 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2006 · Synced Oct 23, 2026, 12:12 PM EDT
Completed Phase 2 Interventional Results available

Antibiotic "Dysbiosis" in Preterm Infants

NCT02784821
View directory record Official record
Conditions
Enterocolitis, Necrotizing, Bacteremia, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Periventricular Leukomalacia, Chronic Lung Disease, Ileal Perforation
Interventions
Antibiotic, Gastric fluid, Breast milk, Stool samples, Antibiotics
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
23 Weeks to 33 Weeks
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 23, 2026, 12:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification

NCT00183001
View directory record Official record
Conditions
Osteoporosis, Vascular Calcification, Inflammation
Interventions
Vitamin K
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years to 80 Years
Enrollment
452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2009 · Synced Oct 23, 2026, 12:12 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

NCT04610892
View directory record Official record
Conditions
Coronary Heart Disease (CHD)
Interventions
MEDI6570, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Mobile, Alabama • Beverly Hills, California • Covina, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 23, 2026, 12:12 PM EDT
Withdrawn Not applicable Interventional

Low-Level Transcutaneous Vagus Stimulation in ST Segment Elevation Myocardial Infarction: TREAT MI Study

NCT03284281
View directory record Official record
Conditions
STEMI - ST Elevation Myocardial Infarction, Inflammation
Interventions
Tragus stimulator, Sham Tragus stimulator
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 23, 2026, 12:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies

NCT06454344
View directory record Official record
Conditions
Adverse Childhood Experiences, Vascular Dilatation, Sleep, Sleep Disturbance, Psychosocial Stressor, Psychological Trauma, Endothelial Dysfunction, Inflammation, Oxidative Stress
Interventions
Cognitive Behavioral Therapy for Insomnia (CBT-i)
Behavioral
Lead sponsor
Nathaniel Jenkins
Other
Eligibility
18 Years to 29 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 23, 2026, 12:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation

NCT01550432
View directory record Official record
Conditions
Obesity, Hyperlipidemia, Insulin Resistance, Hypertension
Interventions
Glutathione, N-Acetylcysteine, Placebo
Dietary Supplement · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 23, 2026, 12:12 PM EDT
Completed Not applicable Interventional Results available

Statin Therapy to Improve Atherosclerosis in HIV Patients

NCT00965185
View directory record Official record
Conditions
Cardiovascular Disease, HIV, Atherosclerosis, Inflammation, Statins, HMG-CoA, HIV Infections
Interventions
atorvastatin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 23, 2026, 12:12 PM EDT
Withdrawn No phase listed Observational

Collective Accuryn Physiologic Signals and Signatures

NCT03817281
View directory record Official record
Conditions
Critical Illness, Acute Kidney Injury, Sepsis, Septic Shock, Abdominal Compartment Syndrome
Interventions
Accuryn Monitoring System
Device
Lead sponsor
Potrero Medical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 23, 2026, 12:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)

NCT04790240
View directory record Official record
Conditions
Covid19 Virus Infection
Interventions
Inflammation (I), Inflammation (II), Inflammation (III), Standard of care
Dietary Supplement · Drug
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 23, 2026, 12:12 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Center of Research Translation (CORT) Project 2

NCT02038179
View directory record Official record
Conditions
Pre-hypertension, JNC 7 Stage I Hypertension
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 40 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 23, 2026, 12:12 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 23, 2026, 12:12 PM EDT